BenevolentAI Investor Day Presentation Deck
BEN-2293 - Atopic Dermatitis (AD)
• Atopic dermatitis is the most common chronic
inflammatory skin disease, characterized by intensely
itchy, red, and swollen skin(¹)
o Affects 10-20% of children and up to 3% of adults(2)
o Approximately 60-70% of all cases present with
mild-moderate disease severity(3)
o Prevalence is rising (3), with market value in 7MM
forecast to exceed $14 billion (2,4)
Skin inflammation and chronic pruritus associated
with atopic dermatitis negatively impact quality of life
and psychosocial well-being(¹)
• Clear unmet need in mild to moderate patient
segment for treatment addressing itch and
inflammation, without side effects of steroids
Photo Source:https://www.bmj.c
Sources: (1) Weidinger et al. Nat Rev Dis Primers 2018; (2) Global Data Report 2018: Atopic Dermatitis: Global Drug Forecast and
Market Analysis to 2027; (3) Global Data Report 2018: Atopic Dermatitis: Epidemiology Forecast to 2027; (4) Evaluate Pharma
Benevolent 42View entire presentation